Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 1603

Cardiovascular-related disorders are a significant worldwide health problem. Cardiovascular disease (CVD) is the leading cause of death in developed countries, making up a third of the mortality rate in the US1. Congenital heart defects (CHD) affect ∼1% of all live births2, making it the most common birth defect in humans. Current technologies provide some insight into how these disorders originate but are limited in their ability to provide a complete overview of disease pathogenesis and progression due to their lack of physiological complexity. There is a pressing need to develop more faithful organ-like platforms recapitulating complex in vivo phenotypes to study human development and disease in vitro. Here, we report the most faithful in vitro organoid model of human cardiovascular development to date using human pluripotent stem cells (hPSCs). Our protocol is highly efficient, scalable, shows high reproducibility and is compatible with high-throughput approaches. Furthermore, our hPSC-based heart organoids (hHOs) showed very high similarity to human fetal hearts, both morphologically and in cell-type complexity. hHOs were differentiated using a two-step manipulation of Wnt signaling using chemical inhibitors and growth factors in completely defined media and culture conditions. Organoids were successfully derived from multiple independent hPSCs lines with very similar efficiency. hHOs started beating at ∼6 days, were mostly spherical and grew up to ∼1 mm in diameter by day 15 of differentiation. hHOs developed sophisticated, interconnected internal chambers and confocal analysis for cardiac markers revealed the presence of all major cardiac lineages, including cardiomyocytes (TNNT2+), epicardial cells (WT1+, TJP+), cardiac fibroblasts (THY1+, VIM+), endothelial cells (PECAM1+), and endocardial cells (NFATC1+). Morphologically, hHOs developed well-defined epicardial and adjacent myocardial regions and presented a distinct vascular plexus as well as endocardial-lined microchambers. RNA-seq time-course analysis of hHOs, monolayer differentiated iPSCs and fetal human hearts revealed that hHOs recapitulate human fetal heart tissue development better than previously described differentiation protocols3,4. hHOs allow higher-order interaction of distinct heart tissues for the first time and display biologically relevant physical and topographical 3D cues that closely resemble the human fetal heart. Our model constitutes a powerful novel tool for discovery and translational studies in human cardiac development and disease.

The authors have declared no competing interest.

Read more | >

Antibiotic resistance is a global human health threat, causing routine treatments of bacterial infections to become increasingly difficult. The problem is exacerbated by biofilm formation by bacterial pathogens on the surfaces of indwelling medical and dental devices that facilitate high levels of tolerance to antibiotics. The development of new antibacterial nanostructured surfaces shows excellent prospects for application in medicine as next-generation biomaterials. The physico-mechanical interactions between these nanostructured surfaces and bacteria lead to bacterial killing or prevention of bacterial attachment and subsequent biofilm formation, and thus are promising in circumventing bacterial infections. This Review explores the impact of surface roughness on the nanoscale in preventing bacterial colonization of synthetic materials and categorizes the different mechanisms by which various surface nanopatterns exert the necessary physico-mechanical forces on the bacterial cell membrane that will ultimately result in cell death.

Read more | >

Using the venom from 312 honeybees and bumblebees in Perth Western Australia, Ireland and England, Dr. Ciara Duffy from the Harry Perkins Institute of Medical Research and The University of Western Australia, tested the effect of the venom on the clinical subtypes of breast cancer, including triple-negative breast cancer, which has limited treatment options.

Results published in the prestigious international journal npj Precision Oncology revealed that honeybee venom rapidly destroyed triple-negative breast and HER2-enriched .

Dr. Duffy said the aim of the research was to investigate the anti-cancer properties of honeybee venom, and a component compound, melittin, on different types of breast cancer cells.

Read more | >

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), causing coronavirus disease 2019 (Covid-19), emerged in December 2019.1 Seroconversion of most patients with Covid-19 occurs between 7 and 14 days after diagnosis.2,3 A study of 61,000 persons in Spain showed that 5% of the population had formed antibodies against the spike and nucleoproteins and that approximately one third of infected persons were asymptomatic.4 It was suggested that a substantial fraction of those infected become antibody-negative early in the convalescence period.5 Several studies have reported a higher prevalence4 and levels3,5 of SARS-CoV-2 antibodies in severely ill patients than in those with no or mild symptoms.

The infection fatality risk of SARS-CoV-2 is difficult to estimate because the total number of diagnosed and undiagnosed cases is needed as the denominator. The infection fatality risk was reported as 0.4% in a small German town after carnival festivities,6 0.6% on the Diamond Princess cruise ship,7 and 0.66% in China.8

Well-validated serologic assays for SARS-CoV-2 are urgently needed. Several small comparative studies of commercial SARS-CoV-2 antibody assays have been published.9–12 A highly specific assay is required for screening populations with a low seroprevalence, such as that in Iceland.

Read more | >

Here’s my latest video!

Germ-free mice (animals don’t have a microbiome) live longer than microbiome-containing mice, but it’s impractical for people to live in a bubble for their entire lifespan. As a more practical approach, which microbiome-derived factors impact lifespan, and can they be modified?

Dietary supplementation with acarbose increases lifespan, and one reason for that may involve reduced circulating levels of glucose, but the other side of that story involves increased gut bacterial production of short chain fatty acids (SCFAs). Whether acarbose will increase lifespan in people is unknown, and with the goal of increasing lifespan, are there other ways to increase SCFAs?

Continue reading “The Impact Of The Microbiome On Lifespan” | >

Nature has spent millennia honing the virus into a ruthlessly efficient delivery vehicle for nucleic acids. Viruses have even been harnessed for our own delivery purposes. But some applications have had only mixed success. For example, commercial applications of genetic engineering, which require high scalability, low cost, and impeccable safety, remain a challenge.

Although they can easily enter the body and inject their payload into cells, viruses may stimulate a dangerous immune reaction and cause long-term medical complications. In addition, viruses can be expensive and time consuming to cultivate.

Safer and more practical alternatives to viruses are being sought by innovative companies. For example, these companies are developing nonviral gene delivery systems that incorporate nanoparticle formulations, ultrasound, and electric fields. These systems can slip bits of genetic material into cells efficiently and cost-effectively in a range of applications.

Read more | >

But U.S. is not the only country engaged in human enhancement and transhumanism, as Russia and China are also in hot pursuit with exoskeletons, vaccines and brain implants. As this competition gains traction, one wonders what the future of their militaries may look like as human beings are steadily integrated with machines to become armies of iron man.

From the blog of Christina Lin at The Times of Israel.

Read more | >

A recent study in Science Advances by researchers at Karolinska Institutet and Max Planck Institute, shows that neurons can counteract degeneration and promote survival by adapting their metabolism. It challenges the long-standing view that neurons cannot adjust their metabolism and therefore irreversibly degenerate. These findings may contribute to developing therapeutic approaches for patients with mitochondrial diseases and other types of neurodegeneration, such as Parkinson’s Disease.

Mitochondria are the power plants of our and play an important role in providing energy for normal function of the tissues in our body. Nerve cells are particularly dependent on mitochondria for their activity. A growing body of evidence has linked mitochondrial dysfunction to some of the most devastating forms of , such as Parkinson’s , different ataxias and several peripheral neuropathies.

However, despite the urge to find strategies to prevent or arrest neurodegeneration, our understanding of the precise events underlying neuronal death caused by mitochondrial dysfunction is very limited.

Read more | >

We look forward to collaborating closely with Proton International on these new centers and providing greater access to this lifesaving technology to patients in Texas and the Southeast.”

The new centers will feature the MEVION S250i Proton Therapy System® with HYPERSCAN® Pencil Beam Scanning (PBS). HYPERSCAN enables faster and sharper delivery of therapeutic radiation to tumors. The system’s leading-edge clinical capabilities, combined with its compact, affordable design, and industry-leading ramp-up time, has changed the landscape of proton therapy. Today, more cancer centers are considering providing compact proton therapy to their patients because of the technology Mevion has advanced.

One key difference between X-ray or photon radiation therapy and proton therapy is already known. It goes to the very core of why proton therapy is beneficial. It’s not that it kills cancer better; it’s that it damages normal cells less.

LITTLETON, Mass.—()—Mevion Medical Systems and Proton International announced today that they have signed a two-system contract to bring Mevion’s compact proton therapy solution to new centers in locations to be announced in South Texas and the Southeast United States.

Continue reading “Mevion and Proton International to Partner on Two Proton Therapy Centers” | >